Search hospitals > North Carolina > Goldsboro
Southeastern Medical Oncology Center-Goldsboro
Claim this profileGoldsboro, North Carolina 27534
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
237 reported clinical trials
3 medical researchers
Summary
Southeastern Medical Oncology Center-Goldsboro is a medical facility located in Goldsboro, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Southeastern Medical Oncology Center-Goldsboro is involved with conducting 237 clinical trials across 406 conditions. There are 3 research doctors associated with this hospital, such as Samer S. Kasbari, James Atkins, MD, and Nagesh H. Jayaram.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Samer S. KasbariSoutheastern Medical Oncology Center-Clinton5 years of reported clinical research
Expert in Cancer
Expert in Adenocarcinoma
72 reported clinical trials
132 drugs studied
James Atkins, MDSoutheastern Medical Oncology Center10 years of reported clinical research
Studies Ductal Carcinoma
Studies Breast Cancer
5 reported clinical trials
9 drugs studied
Nagesh H. JayaramSoutheastern Medical Oncology Center-Clinton8 years of reported clinical research
Studies Colorectal Cancer
Studies Adenoma
2 reported clinical trials
6 drugs studied
Clinical Trials running at Southeastern Medical Oncology Center-Goldsboro
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Laryngeal Cancer
Bladder Cancer
Colon Cancer
Squamous Cell Carcinoma
Tumors
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Southeastern Medical Oncology Center-Goldsboro?
Southeastern Medical Oncology Center-Goldsboro is a medical facility located in Goldsboro, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Southeastern Medical Oncology Center-Goldsboro is involved with conducting 237 clinical trials across 406 conditions. There are 3 research doctors associated with this hospital, such as Samer S. Kasbari, James Atkins, MD, and Nagesh H. Jayaram.